NASDAQ : HUMA
Humacyte, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.4112 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 114.23M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 114.23M |
| Enterprise Value | 101.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 277.80M |
| Shares Outstanding | 277.80M |
| Shares Change (YoY) | +45.78% |
| Shares Change (QoQ) | +18.37% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 27.00% |
| Float | 250.79M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 53.86 |
| Forward PS | 15.55 |
| PB Ratio | 3.65 |
| P/TBV Ratio | 3.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 47.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.21 |
| Quick Ratio | 5.37 |
| Debt / Equity | 2.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.73 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -547.87% |
| Return on Assets (ROA) | -49.87% |
| Return on Invested Capital (ROIC) | -74.17% |
| Return on Capital Employed (ROCE) | -89.70% |
| Weighted Average Cost of Capital (WACC) | 16.47% |
| Revenue Per Employee | $11,527 |
| Profits Per Employee | -$525,370 |
| Employee Count | 184 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 9.03 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.68 |
| 52-Week Price Change | -75.67% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 41.85 |
| Average Volume (20 Days) | 6,368,605 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 30.25M |
| Short Previous Month | 29.40M |
| Short % of Shares Out | 10.89% |
| Short % of Float | 12.06% |
| Short Ratio (days to cover) | 4.96 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.12M |
| Gross Profit | -79.37M |
| Operating Income | -110.46M |
| Pretax Income | -96.74M |
| Net Income | -96.67M |
| EBITDA | -103.23M |
| EBIT | -110.46M |
| Loss Per Share | -$0.50 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 79.90M |
| Total Debt | 66.88M |
| Net Cash | 13.02M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 31.26M |
| Book Value Per Share | 0.11 |
| Working Capital | 77.84M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -97.19M |
| Capital Expenditures | -367,000 |
| Depreciation & Amortization | 7.23M |
| Net Borrowing | 38.22M |
| Free Cash Flow | -97.56M |
| FCF Per Share | -$0.35 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -5,207.78% |
| Pretax Margin | -4,560.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -45.78% |
| Shareholder Yield | n/a |
| Earnings Yield | -120.90% |
| FCF Yield | -85.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.63 |
| Price Target Difference | 295.19% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 279.06% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.48 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |